Randomized study of Navelbine® and cisplatin versus vindesine and cisplatin versus Navelbine® alone in 612 patients with advanced non-small cell lung cancer (NSCLC);RESULTATS D'UNE ETUDE RANDOMISEE COMPARANT L'ASSOCIATION NAVELBINE®-CISPLATINUM A L'ASSOCIATION VINDESINE-CISPLATINUM ET A LA NAVELBINE® SEULE CHEZ 612 MALADES PORTEURS D'UN CARCINOME BRONCHIQUE NON A PETITES CELLULES INOPERABLE

Bulletin du Cancer

Volumn 83, Issue 5, 1996, Pages 385-394

  Le Chevalier, T ^a   Brisgand, D ^a   Pujol, J L ^b   Douillard, J Y ^c   Monnier, A ^d   Riviere A ^e   Chomy, P ^f   Le Groumellec, A ^g   Ruffie, P ^a   Gottfried, M ^a   Gaspard, M H ^h   Chevreau, C ⁱ   Alberola, V ^j   Cigolari, S ^k   Besson, F ^l   Martinez, A ^l   Besenval, M ^l   Berthaud, P ^a   Tursz, T ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Centre Hospitalier l'Aiguelongue   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d Centre Hospitalier A Bouloche   (France)

^e CENTRE FRANÇOIS BACLESSE   (France)

^f INSTITUT BERGONIÉ   (France)

^g Centre Hospitalier P Chubert   (France)

^h CENTRE ANTOINE LACASSAGNE   (France)

ⁱ INSTITUT CLAUDIUS REGAUD   (France)

^j HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^k FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^l INSTITUT DE RECHERCHE PIERRE FABRE   (France)

more..

Author keywords

advanced non small cell lung cancer; cisplatinum; navelbine

Indexed keywords

CISPLATIN; NAVELBINE; VINDESINE; ANTINEOPLASTIC AGENT; VINBLASTINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL; CANCER STAGING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG TOLERANCE; LUNG TUMOR; MIDDLE AGED; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; SURVIVAL RATE; VINBLASTINE; VINDESINE;

EID: 0030147521     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Berthaud P, Le Chevalier T, Ruffié P et al. Phase I-II study of Navelbine® (Vinorelbine®) plus cisplatin In advanced non-small cell lung cancer. Eur J Cancer 1992;28A; 11:1863-5
2. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1991;41:19-36
3. Briancon S, Lamaze R, Barral D et al. Vindesine et chimiothérapie des cancers bronchiques non microcellulaires au stade III. Ann Med Nancy Est 1983;22:639-43
4. Cellerino R, Tummarello D, Guidi F et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991;9:1453-61
5. Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc, Series B 1972;34:187-220
6. Cros S, Wright M, Morimoto M et al. Experimental antitumor activity of Navelbine®. Sem Oncol 1989;16 (4 Suppl):15-20
7. Depierre A, Lemarie E, Dabouis G et al. A phase II study of Navelbine® (Vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991;14:115-9
8. Dhingra HM, Valdivieso M, Carr DT et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1985;3:176-83
9. Einhorn LH, Loehrer PJ, Williams SD et al. Random prospective study of Vindesine versus Vindesine plus high dose cisplatin versus Vindesine plus cisplatin plus mitomycine C in advanced non small cell lung cancer. J Clin Oncol 1986;4:1037-43
10. Elliott JA, Ahmedzai S, Hole D et al. Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur J Cancer Clin Oncol 1984; 20:1025-32
11. Feld R. Quality of life in patients with non small cell lung cancer treated with chemotherapy. Eur J Cancer Clin Oncol 1987;23:357-59
12. Ganz PA, Figlin RA, Haskell CM et al. Supportive care versus supportive care and combination chemotherapy in metastatic non small cell lung cancer: does chemotherapy make a difference? Cancer 1989;63:1271-78
13. Gralla RJ, Casper ES, Kelsen DP et al. Cisplatin and Vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Int Med 1981;95:414-20
14. Hong WK, Pennacchio J, Pugatch R et al. Vindesine versus vindesine with cis-platinum in metastatic non-small cell lung cancer. Proceedings of the International Vinca Alkaloid Symposium: Vindesine. Basel: S. Karger, 1981
15. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, Inc, 1989.
16. Ihde DC, Minna JD. Non-small cell lung cancer. I. Biology, diagnosis and staging. Curr Probl Cancer 1991;15:61-104
17. Jaakkimainen L, Goodwin PJ, Pater J et al. Counting the costs of chemotherapy in a National cancer institute of Canada randomized trial in non small cell lung cancer. J Clin Oncol 1990;8:1301-9
18. Kaasa S, Lund E, Thorud E et al. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 1991;67:2443-7
19. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time date. New York: John Wiley & Sons, Inc, 1980
20. Klastersky J, Sculier JP. Non surgical combined modality therapies in non-small cell lung cancer. Chest 1986; 89(Suppl):289-94
21. Kris MG, Gralla RJ, Kalman LA et al. Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 1985;69:387-95
22. Mangeney P., Andriamialisoa RZ, Langlois N et al. A new class of anti-tumor compounds: 5′Nor and 5′-6′Sec derivatives of vinblastine-type alkaloïds. J Org Chem 1979;44: 3765-8
23. Mantel N. Chi-square tests with one degree of freedom; extensions of the mantel-Haenszel procedure. J Am Stat Assoc 1963;58:690-700
24. Quoix E, Dietmann A, Charbonneau J et al. La chimiothérapie comportant du cisplatine est-elle utile dans le cancer bronchique non mirocellulaire au stade IV? Résultats d'une étude randomisée. Bull Cancer 1991;78:341-6
25. Rapp E, Pater J, William A et al. Chemotherapy can prolong survival in patients with advanced non small cell lung cancer. Report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-41
26. Ries LAG, Hankey BF, Miller BA, Hartman AM, Edwards BK. Cancer statistics review 1973-1988. Bethesda, Md: National Cancer Institute, 1991 (NIH publication 91.2789)
27. Ruckdeschel JC, Finkelstein DM, Ettinger DS et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol, 1986;4: 14-22
28. Shinkai T, Saijo N, Tominaga K et al. Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep 1985;69:945-51
29. Sorensen JB, Osterlind K, Hansen HH. Vinca alkaloids in the treatment of non small cell lung cancer. Cancer Treat Rev 1987;14:29-51
30. WHO handbook for reporting results of cancer treatment. Geneva: WHO Offset Publication, 1979, no 48
31. Woods RL, Williams CJ, Levi J et al. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990; 61:608-11